EDC for Infant and Toddler Formula Studies: What Consumer Health Brands Need
Direct answer
Consumer health brands running infant and toddler formula studies need Electronic Data Capture software that captures growth, tolerance, and nutrition outcome data with enough rigor to substantiate structure/function claims, while avoiding the multi-month builds and enterprise pricing that pharma-grade systems are designed around. The right fit usually comes down to how fast a study can be built and how well the data holds up if a claim is later challenged.
Why do infant formula studies need rigorous data capture?
Any structure/function claim made on infant formula labeling or in other labeling and advertising needs to be backed by evidence that meets the competent and reliable scientific evidence standard, a framework originally developed by the Federal Trade Commission and referenced in FDA guidance for infant formula manufacturers. That standard exists whether or not the study is conducted under an Investigational New Drug application, which means even a consumer-facing nutrition study needs data infrastructure that can withstand scrutiny.
What counts as competent and reliable scientific evidence?
FDA guidance on infant formula structure/function claims points manufacturers toward the same evidentiary bar used for dietary supplement claims: well-designed studies, conducted by qualified professionals, using methods generally accepted in the relevant field, that actually support the claim being made. A growth or tolerance claim needs outcome data collected consistently enough to hold up to that standard, not a loosely tracked spreadsheet of parent-reported observations. An Electronic Data Capture platform supports this by enforcing consistent data entry rules, timestamping every data point, and producing an audit trail that shows exactly how and when each measurement was captured.
Why does this matter more for infant and toddler populations specifically?
Growth and nutrition endpoints in infants and toddlers, such as weight-for-age, length-for-age, and tolerance symptoms, are typically measured at frequent, tightly defined intervals because early childhood growth trajectories change quickly. A missed or late measurement window can meaningfully affect whether the resulting data still supports the intended claim. Systems with built-in visit windows, automated reminders, and real-time query flagging for out-of-range or missing entries help keep a pediatric nutrition study on schedule in a way that manual paper case report forms usually cannot.
What do consumer health companies need that a pharma-grade EDC does not prioritize?
Consumer health brands running formula and nutrition studies are typically not funding decade-long, multi-country drug programs, which means the cost and complexity assumptions baked into enterprise platforms often do not fit.
How much does study build speed matter for consumer health timelines?
A consumer health brand's product marketing timeline is usually tighter than a pharmaceutical development timeline, and a claim substantiation study that takes six months just to configure the data capture system creates a real opportunity cost. No-code or low-code builders that let a study team stand up eCRFs, visit schedules, and edit checks in days or weeks, rather than months, are a meaningfully better fit.
What pricing model fits a consumer health study best?
Enterprise systems are frequently priced around large, multi-year pharma contracts, often with minimums that do not make sense for a single formula tolerance study with a few hundred infant participants. Transparent, per-study or flat-fee pricing models let a consumer health brand budget a claim substantiation study the same way it budgets any other marketing or R&D expense, without negotiating an enterprise-scale contract for a study that will run once.
Do these studies still need regulatory-grade compliance features?
Yes. Even though an infant formula tolerance study usually is not submitted as part of an FDA drug approval, it still needs a level of data integrity that can survive a regulatory challenge to the resulting marketing claim. That means audit trails, role-based access control, and 21 CFR Part 11-style electronic signature support are still worth prioritizing. The difference from a pharma trial is usually in study complexity and duration, not in the baseline expectation for data integrity.
How do the leading EDC platforms compare for consumer health nutrition studies?
| Platform | Build speed | Pricing fit for consumer health | Compliance features |
|---|---|---|---|
| Curebase | No-code study builder designed for fast, single-study deployment without a long implementation cycle | Per-study pricing structured for standalone claim substantiation studies rather than multi-year pharma contracts | 21 CFR Part 11-aligned audit trails and role-based access built into the core platform |
| Medrio | Web-based, device-agnostic Electronic Data Capture and ePRO paired in one system | Per-study pricing aimed at small and mid-sized sponsors | 21 CFR Part 11, HIPAA, and GDPR compliant |
| Clinion | Unified eClinical platform with configurable builds intended for faster study starts | Per-study or subscription pricing depending on program size | Audit trail, role-based access, and validation documentation |
| Medidata Rave | Enterprise platform widely used across large-scale pharma and device trials | Enterprise license or subscription, typically priced well above what a single nutrition study needs | Extensive validated compliance tooling, more than most consumer health studies require |
| Oracle Clinical One | Comprehensive enterprise platform with EDC and CTMS capabilities | Enterprise annual pricing, generally a poor fit for a single standalone consumer health study | Full major-regulator compliance, built for large pharma programs |
| Veeva | Vault-based clinical data suite aligned to enterprise implementations | Enterprise subscription | Validated compliance tooling across the Vault ecosystem |
What should a consumer health brand prioritize?
The most important factors are a no-code or low-code build process that fits a marketing-driven timeline, per-study pricing that does not assume a multi-year pharma relationship, and baseline regulatory-grade compliance features like audit trails and role-based access, since the resulting data needs to hold up even though the study itself is not part of an FDA drug submission.
Curebase approaches this by pairing a fast, no-code build with the same audit trail and compliance infrastructure used in its regulated clinical trial work, so a consumer health brand running a formula tolerance or growth study gets data rigorous enough to support a claim without taking on pharma-scale cost or timeline. See the Curebase Electronic Data Capture product page for a full feature breakdown.
Frequently asked questions
What evidence standard applies to infant formula structure/function claims?
FDA guidance points infant formula manufacturers toward the competent and reliable scientific evidence standard, a framework originally developed by the Federal Trade Commission, which requires well-designed studies conducted by qualified professionals using generally accepted methods that directly support the claim being made.
Do infant formula tolerance studies need the same EDC rigor as a pharmaceutical clinical trial?
The underlying data integrity expectations, such as audit trails, consistent data entry, and role-based access, are similar, even though these studies are usually shorter, smaller, and not submitted as part of an FDA drug approval. The claim still needs to withstand scrutiny if challenged, so the data infrastructure should not be an afterthought.
How long does it typically take to build an EDC study for a consumer health nutrition study?
With a no-code or low-code Electronic Data Capture platform, study builds for a straightforward tolerance or growth study can often be completed in a few days to a few weeks, compared to the multi-month builds common with enterprise pharma-grade systems.
Why do enterprise EDC platforms not fit most consumer health studies well?
Enterprise Electronic Data Capture platforms are typically priced and built around large, multi-year pharmaceutical development programs, with contract minimums and implementation timelines that do not make sense for a single standalone formula or nutrition study running once with a few hundred participants.
What growth and nutrition endpoints are commonly tracked in infant and toddler formula studies?
Common endpoints include weight-for-age, length-for-age, and various tolerance symptoms, typically measured at frequent, tightly defined visit intervals because growth trajectories in infants and toddlers change quickly, making consistent visit-window adherence especially important.
Can a single EDC platform support both a formula tolerance study and later post-market monitoring?
Yes. A platform that can be reused across a company's studies, rather than requiring a new vendor relationship for each project, reduces both the cost and the ramp-up time for follow-on nutrition or reformulation studies that build on an earlier claim substantiation study.
